Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + pazopanib
- Development stage
- Phase 1
- Lead developer
- Unicancer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination of cisplatin, a platinum-based chemotherapy agent, and pazopanib, a multi-tyrosine kinase inhibitor. This combination has been studied in clinical trials for patients with advanced solid tumors. The maximum tolerated dose was determined to be 400 mg of pazopanib and 75 mg/m² of cisplatin. However, significant pharmacokinetic interactions were observed, with pazopanib metabolism being affected by the cisplatin regimen, likely due to competitive inhibition by aprepitant, an antiemetic drug administered with cisplatin.
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)DNA
Beyond the preview
Go deeper on cisplatin + pazopanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + pazopanib.